Tweenvest Stocks

Larimar Therapeutics, Inc. (NasdaqGM: LRMR)

Health Care · Biotechnology · US

$4.13

+1.85% today · +8.9% 1Y

Larimar Therapeutics, Inc. (NasdaqGM: LRMR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $422.75M and employs 71 people.

Over the last twelve months the share price has gained 8.9%, trading between 2.72 and 6.42.

Tweenvest scores Larimar Therapeutics, Inc. across four factors: quality 27/100. Its strongest factor is quality.

LRMR price history

Not enough price history to draw a chart yet.

Key figures

Market cap
$422.75M
Revenue (TTM)
P/E
EPS
-1.93
Dividend yield
Beta (5Y)
0.75
52-week high
$6.42
52-week low
$2.72
Avg volume (3M)
Shares outstanding
104.38M
Employees
71
Next earnings

About Larimar Therapeutics, Inc.

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.

ISIN
US5171251003
Listed since
Jun 19, 2014
Exchange
Nasdaq Global Market
Currency
USD
CompanyMarket capPriceDay
AbbVie Inc.NYSE: ABBV$467.44B$266.29+0.67%
Amgen Inc.NasdaqGS: AMGN$239.95B$445.02+0.27%
Gilead Sciences, Inc.NasdaqGS: GILD$181.95B$148.42+1.14%
Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX$138.79B$555.26+1.40%
Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN$82.73B$837.90+1.13%
argenx SEENXTBR: ARGX$63.06B879.20+1.74%
CSL LimitedASX: CSL$57.94BAU$169.11+0.48%
Moderna, Inc.NasdaqGS: MRNA$55.45B$157.60+13.47%

Browse every Biotechnology company →

Figures last refreshed Aug 18, 2026.